“LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING”, Mediterr J Hematol Infect Dis, vol. 13, no. 1, p. e2021065, Oct. 2021, doi: 10.4084/MJHID.2021.065.